Betaxolol: Difference between revisions
(Creation of page) |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Beta blocker]] | *Type: [[Beta blocker]] | ||
*Dosage Forms: 10, 20 mg | *Dosage Forms: 10 mg, 20 mg, 0.5% ophthalmic solution, 0.25% suspension | ||
*Routes of Administration: Oral | *Routes of Administration: Oral, ophthalmic | ||
*Common Trade Names: Kerlone | *Common Trade Names: Kerlone | ||
==Adult Dosing== | ==Adult Dosing== | ||
* | *5-80 mg PO daily | ||
* | *1-2 drops in affected eye BID | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''Safety/efficacy of oral forms and 0.5% solution not established in peds'' | |||
*0.25% suspension: 1 drop in affected eye BID | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C; Caution advised in 2nd and 3rd trimesters. Risk of intrauterine growth restriction and neonatal adverse effects including bradycardia and hypoglycemia. | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C; Caution advised in 2nd and 3rd trimesters. Risk of intrauterine growth restriction and neonatal adverse effects including bradycardia and hypoglycemia. | ||
*[[Lactation risk categories|Lactation risk]]: L3; Safety unknown | *[[Lactation risk categories|Lactation risk]]: L3; Safety unknown | ||
*Severe renal impairment: Start at 5mg PO daily, increase by 5mg/day q2wk to max daily dose 20mg | |||
*Hepatic dosing: no adjustment | |||
* | |||
* | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Sinus [[bradycardia]] | *Sinus [[bradycardia]], 2nd or 3rd degree [[AV block]], [[sick sinus syndrome]] (without pacemaker) | ||
*Decompensated [[heart failure]], [[cardiogenic shock]] | |||
*Decompensated [[heart failure]] | *Untreated [[pheochromocytoma]] | ||
*[[ | |||
*Avoid abrupt withdrawal | *Avoid abrupt withdrawal | ||
| Line 40: | Line 29: | ||
===Serious=== | ===Serious=== | ||
*[[CHF]] | *[[CHF]] | ||
*[[ | *Severe [[bradycardia]], [[heart block]] | ||
*[[Angina]] exacerbation, ventricular arrythmia, or [[MI]] with abrupt discontinuation | |||
*[[Angina]] exacerbation | |||
*Bronchospasm | *Bronchospasm | ||
*Hypersensitivity reaction | *Hypersensitivity reaction | ||
*[[Psoriasis]] exacerbation, [[lupus]] erythematosus, Raynaud's phenomenon | |||
*[[Psoriasis]] exacerbation | |||
===Common=== | ===Common=== | ||
*[[Bradycardia]] | *[[Bradycardia]], [[chest pain]] | ||
*[[Headache]] | *[[Headache]], [[dizziness]], [[fatigue]] | ||
*[[Dyspepsia]] | *[[Dyspepsia]], [[diarrhea]] | ||
*[[Arthralgia]] | *[[Arthralgia]] | ||
*[[ | *[[URI]], [[pharyngitis]] | ||
*[[Dyspnea]] | *[[Dyspnea]] | ||
==Pharmacology== | ==Pharmacology== | ||
| Line 71: | Line 48: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Selectively antagonizes beta-1 adrenergic receptors. | *Selectively antagonizes beta-1 adrenergic receptors. | ||
==Comments== | ==Comments== | ||
==See Also== | ==See Also== | ||
*[[Beta-blockers]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 02:20, 11 December 2016
Administration
- Type: Beta blocker
- Dosage Forms: 10 mg, 20 mg, 0.5% ophthalmic solution, 0.25% suspension
- Routes of Administration: Oral, ophthalmic
- Common Trade Names: Kerlone
Adult Dosing
- 5-80 mg PO daily
- 1-2 drops in affected eye BID
Pediatric Dosing
Safety/efficacy of oral forms and 0.5% solution not established in peds
- 0.25% suspension: 1 drop in affected eye BID
Special Populations
- Pregnancy Rating: C; Caution advised in 2nd and 3rd trimesters. Risk of intrauterine growth restriction and neonatal adverse effects including bradycardia and hypoglycemia.
- Lactation risk: L3; Safety unknown
- Severe renal impairment: Start at 5mg PO daily, increase by 5mg/day q2wk to max daily dose 20mg
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- Sinus bradycardia, 2nd or 3rd degree AV block, sick sinus syndrome (without pacemaker)
- Decompensated heart failure, cardiogenic shock
- Untreated pheochromocytoma
- Avoid abrupt withdrawal
Adverse Reactions
Serious
- CHF
- Severe bradycardia, heart block
- Angina exacerbation, ventricular arrythmia, or MI with abrupt discontinuation
- Bronchospasm
- Hypersensitivity reaction
- Psoriasis exacerbation, lupus erythematosus, Raynaud's phenomenon
Common
- Bradycardia, chest pain
- Headache, dizziness, fatigue
- Dyspepsia, diarrhea
- Arthralgia
- URI, pharyngitis
- Dyspnea
Pharmacology
- Half-life: 14-22 hr
- Metabolism: Liver extensively; CYP450: Unknown
- Excretion: Urine > 80% (15% unchanged)
Mechanism of Action
- Selectively antagonizes beta-1 adrenergic receptors.